NO2009013I2 - Laropiprant eller et farmasøytisk akseptabelt saltderav - Google Patents

Laropiprant eller et farmasøytisk akseptabelt saltderav

Info

Publication number: NO2009013I2
Authority: NO; Norway
Prior art keywords: laropiprant; pharmaceutically acceptable; acceptable salt; salt; pharmaceutically
Prior art date: 2002-01-24

Application number

NO2009013C

Other languages

English (en)

Other versions

NO2009013I1 (no

Original Assignee

Merck Frosst Canada Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-24

Filing date

2009-06-19

Publication date

2012-08-27

2009-06-19 Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd

2009-06-29 Publication of NO2009013I1 publication Critical patent/NO2009013I1/no

2012-08-27 Publication of NO2009013I2 publication Critical patent/NO2009013I2/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Otolaryngology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Obesity (AREA)

NO2009013C 2002-01-24 2009-06-19 Laropiprant eller et farmasøytisk akseptabelt saltderav NO2009013I2 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US35138402P	2002-01-24	2002-01-24
PCT/CA2003/000084 WO2003062200A2 (en)	2002-01-24	2003-01-22	Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists

Publications (2)

Publication Number	Publication Date
NO2009013I1 NO2009013I1 (no)	2009-06-29
NO2009013I2 true NO2009013I2 (no)	2012-08-27

Family

ID=27613492

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20043536A NO327322B1 (no)	2002-01-24	2004-08-24	Fluorsubstituert forbindelse og farmasoytisk preparat
NO20071193A NO20071193L (no)	2002-01-24	2007-03-02	Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
NO2009013C NO2009013I2 (no)	2002-01-24	2009-06-19	Laropiprant eller et farmasøytisk akseptabelt saltderav

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
NO20043536A NO327322B1 (no)	2002-01-24	2004-08-24	Fluorsubstituert forbindelse og farmasoytisk preparat
NO20071193A NO20071193L (no)	2002-01-24	2007-03-02	Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister

Country Status (39)

Country	Link
US (6)	US20030158246A1 (no)
EP (3)	EP1470107B1 (no)
JP (2)	JP4008885B2 (no)
KR (2)	KR100859230B1 (no)
CN (3)	CN101092388A (no)
AR (1)	AR038136A1 (no)
AT (1)	ATE414690T1 (no)
AU (1)	AU2003202343B2 (no)
BR (1)	BR0307050A (no)
CA (1)	CA2471952C (no)
CY (3)	CY1108841T1 (no)
DE (2)	DE122009000022I1 (no)
DK (2)	DK1470107T3 (no)
DO (1)	DOP2003000566A (no)
EA (1)	EA006134B1 (no)
EC (1)	ECSP045203A (no)
EG (1)	EG24978A (no)
ES (2)	ES2316717T3 (no)
FR (1)	FR09C0010I2 (no)
GE (1)	GEP20074078B (no)
HR (1)	HRP20040665B1 (no)
IL (3)	IL162825A0 (no)
IS (2)	IS2633B (no)
JO (1)	JO2481B1 (no)
LU (1)	LU91534I2 (no)
MX (1)	MXPA04007167A (no)
MY (1)	MY137040A (no)
NL (1)	NL300377I2 (no)
NO (3)	NO327322B1 (no)
NZ (1)	NZ533786A (no)
PE (1)	PE20030982A1 (no)
PL (1)	PL208527B1 (no)
PT (2)	PT1470107E (no)
RS (2)	RS51672B (no)
SI (2)	SI1470107T1 (no)
TW (1)	TWI259080B (no)
UA (1)	UA75520C2 (no)
WO (1)	WO2003062200A2 (no)
ZA (1)	ZA200404999B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7273883B2 (en) *	2000-09-14	2007-09-25	Allergan, Inc.	Prostaglandin EP4 antagonist
US7217725B2 (en) *	2000-09-14	2007-05-15	Allergan, Inc.	Prostaglandin D2 antagonist
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es) *	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2004104205A2 (en) *	2003-05-16	2004-12-02	Merck & Co., Inc.	Enzymatic preparation of chiral indole esters
AU2004240705A1 (en) *	2003-05-20	2004-12-02	Merck Frosst Canada & Co.	Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
CA2534240A1 (en) *	2003-08-07	2005-02-17	Merck Sharp & Dohme Limited	Treatment for alzheimer's disease and related conditions
TWI258478B (en)	2003-10-31	2006-07-21	Arena Pharm Inc	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
DE602005006539D1 (de)	2004-03-11	2008-06-19	Actelion Pharmaceuticals Ltd	Tetrahydropyridoindolderivate
AU2005230897B2 (en) *	2004-04-02	2011-03-03	Merck Sharp & Dohme Corp.	Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives
GT200500284A (es) *	2004-10-15	2006-03-27	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
US20070299122A1 (en) *	2004-11-08	2007-12-27	Tobert Jonathan A	Method of Treating Pathological Blushing
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
JPWO2006068162A1 (ja) *	2004-12-24	2008-06-12	塩野義製薬株式会社	慢性閉塞性肺疾患の治療剤
SI1833791T1 (sl) *	2004-12-27	2011-11-30	Actelion Pharmaceuticals Ltd	Derivati 2 3 4 9-tetrahidro-1h-karbazola kot antagonisti receptorja crth2
WO2006089309A2 (en) *	2005-02-17	2006-08-24	Merck & Co., Inc.	Method of treating atherosclerosis, dyslipidemias and related conditions
US20090054423A1 (en) *	2005-04-13	2009-02-26	Imbriglio Jason E	Niacin receptor agonists, compositions containing such compounds and methods of treatment
ES2372701T3 (es)	2005-07-22	2012-01-25	Shionogi & Co., Ltd.	Derivado de indol que tiene actividad antagonista del receptor de pgd2.
JP5064219B2 (ja)	2005-07-22	2012-10-31	塩野義製薬株式会社	Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
JP5147401B2 (ja)	2005-09-06	2013-02-20	塩野義製薬株式会社	Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
US9254293B2 (en)	2006-06-16	2016-02-09	The Trustees Of The University Of Pennsylvania	Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH
CN101500996B (zh)	2006-08-07	2012-07-04	埃科特莱茵药品有限公司	(3-胺基-1,2,3,4-四氢-9h-咔唑-9-基)-乙酸衍生物
US20100260841A1 (en) *	2007-02-08	2010-10-14	Paolini John F	Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20090076117A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched laropiprant
JP2011526281A (ja)	2008-06-24	2011-10-06	アミラファーマシューティカルズ，インク．	プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
WO2010030360A1 (en)	2008-09-11	2010-03-18	Arena Pharmaceuticals, Inc.	3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
MX2011003166A (es) *	2008-09-25	2011-04-27	Merck Frosst Canada Ltd	Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4.
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US9180114B2 (en) *	2008-11-26	2015-11-10	President And Fellows Of Harvard College	Neurodegenerative diseases and methods of modeling
US8882678B2 (en) *	2009-03-13	2014-11-11	Atrium Medical Corporation	Pleural drainage system and method of use
MX2012010820A (es)	2010-03-22	2012-10-10	Actelion Pharmaceuticals Ltd	Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2.
ES2596581T3 (es)	2011-04-14	2017-01-10	Actelion Pharmaceuticals Ltd.	Derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético y su uso como moduladores del receptor de prostaglandina D2
JP5841361B2 (ja) *	2011-06-29	2016-01-13	壽製薬株式会社	三環性化合物及びそれを含有する医薬組成物
AR088377A1 (es) *	2011-10-20	2014-05-28	Siena Biotech Spa	Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102659664B (zh) *	2012-03-28	2015-01-21	中国计量学院	合成分离拉洛皮兰及其类似物的方法
FR3000395A1 (fr) *	2012-12-31	2014-07-04	Galderma Res & Dev	Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
FR3000399B1 (fr) *	2012-12-31	2015-03-27	Galderma Res & Dev	Utilisation topique du laropiprant pour le traitement de la rosacee
MY179356A (en)	2014-03-17	2020-11-05	Idorsia Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2015140701A1 (en)	2014-03-18	2015-09-24	Actelion Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP4420734A3 (en)	2015-02-13	2024-11-06	Institut National de la Santé et de la Recherche Médicale	Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
TWI711616B (zh)	2015-09-15	2020-12-01	瑞士商愛杜西亞製藥有限公司	結晶型式
CN111886315B (zh)	2018-03-19	2023-06-30	三井化学株式会社	显示元件用密封材及其固化物、有机el元件用框密封材以及有机el元件用面密封材

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3535326A (en) *	1967-03-06	1970-10-20	Sumitomo Chemical Co	Certain tetrahydro carboline derivatives
BE787444A (fr) *	1971-08-13	1973-02-12	Hoffmann La Roche	Composes polycycliques
US4009181A (en) *	1973-01-22	1977-02-22	Hoffmann-La Roche Inc.	Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) *	1973-10-01	1977-11-08	American Home Products Corporation	Carbazole acetic acid derivatives
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
US5021447A (en) *	1986-01-23	1991-06-04	Merck Frosst Canada, Inc.	Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
IL81325A (en) *	1986-01-23	1990-11-29	Merck Frosst Canada Inc	Tetrahydrocarbazole 1-alkanoic acids and pharmaceutical compositions containing them
US4808608A (en) *	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4940719A (en) *	1986-03-27	1990-07-10	Merck Frosst Canada, Inc.	Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) *	1987-07-21	1988-10-04	Merck & Co., Inc.	Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
US5221678A (en)	1990-07-26	1993-06-22	Merck Frosst Canada, Inc.	(quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en)	1991-01-22	1991-03-06	Erba Carlo Spa	N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
WO1995015973A1 (en)	1993-12-06	1995-06-15	Cytel Corporation	Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en)	1994-07-07	1996-04-23	Texas Biotechnology Corporation	Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
AU2964295A (en)	1994-07-11	1996-02-09	Athena Neurosciences, Inc.	Inhibitors of leukocyte adhesion
US5811391A (en)	1994-08-25	1998-09-22	Cytel Corporation	Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en)	1994-12-24	1996-01-31	Zeneca Ltd	Chemical compounds
US6306840B1 (en)	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
WO1996031206A2 (en)	1995-04-07	1996-10-10	Warner-Lambert Company	Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en)	1995-06-07	1996-12-19	Tanabe Seiyaku Co., Ltd.	CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
TR199701667T2 (xx)	1995-06-21	1999-10-21	Shionogi & Co.,Ltd.	�ift �evrimli amino t�revleri ve bu t�revleri i�eren PGD2 antogonisti.
US6034057A (en)	1995-07-06	2000-03-07	Zeneca Limited	Peptide inhibitors of fibronectine
US6248713B1 (en)	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
CZ297324B6 (cs)	1996-12-13	2006-11-15	Shionogi & Co., Ltd.	Benzothiofenkarboxamidové deriváty a antagonisty PGD2, které je obsahují
JP3857525B2 (ja)	1998-06-03	2006-12-13	塩野義製薬株式会社	Ｐｇｄ２拮抗剤を含有する痒みの治療剤
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
US6410583B1 (en) *	2000-07-25	2002-06-25	Merck Frosst Canada & Co.	Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

2003
- 2003-01-14 AR ARP030100093A patent/AR038136A1/es active IP Right Grant
- 2003-01-16 MY MYPI20030139A patent/MY137040A/en unknown
- 2003-01-16 JO JO20032A patent/JO2481B1/en active
- 2003-01-21 US US10/348,403 patent/US20030158246A1/en not_active Abandoned
- 2003-01-21 PE PE2003000068A patent/PE20030982A1/es not_active Application Discontinuation
- 2003-01-22 ES ES03700740T patent/ES2316717T3/es not_active Expired - Lifetime
- 2003-01-22 RS YU62404A patent/RS51672B/en unknown
- 2003-01-22 KR KR1020047011489A patent/KR100859230B1/ko not_active IP Right Cessation
- 2003-01-22 NZ NZ533786A patent/NZ533786A/en not_active IP Right Cessation
- 2003-01-22 WO PCT/CA2003/000084 patent/WO2003062200A2/en active Application Filing
- 2003-01-22 PT PT03700740T patent/PT1470107E/pt unknown
- 2003-01-22 DE DE122009000022C patent/DE122009000022I1/de active Pending
- 2003-01-22 SI SI200331470T patent/SI1470107T1/sl unknown
- 2003-01-22 AU AU2003202343A patent/AU2003202343B2/en not_active Ceased
- 2003-01-22 CA CA002471952A patent/CA2471952C/en not_active Expired - Fee Related
- 2003-01-22 EP EP03700740A patent/EP1470107B1/en not_active Expired - Lifetime
- 2003-01-22 BR BR0307050-6A patent/BR0307050A/pt not_active IP Right Cessation
- 2003-01-22 IL IL16282503A patent/IL162825A0/xx unknown
- 2003-01-22 PT PT08105552T patent/PT2045241E/pt unknown
- 2003-01-22 MX MXPA04007167A patent/MXPA04007167A/es active IP Right Grant
- 2003-01-22 CN CNA2007101263979A patent/CN101092388A/zh active Pending
- 2003-01-22 CN CNA038026759A patent/CN1902176A/zh active Pending
- 2003-01-22 AT AT03700740T patent/ATE414690T1/de active
- 2003-01-22 EP EP08105552A patent/EP2045241B1/en not_active Expired - Lifetime
- 2003-01-22 RS RSP-2010/0338A patent/RS20100338A/en unknown
- 2003-01-22 JP JP2003562082A patent/JP4008885B2/ja not_active Expired - Fee Related
- 2003-01-22 US US10/502,380 patent/US7317036B2/en not_active Expired - Lifetime
- 2003-01-22 KR KR1020077010548A patent/KR20070056166A/ko not_active Application Discontinuation
- 2003-01-22 DK DK03700740T patent/DK1470107T3/da active
- 2003-01-22 PL PL370427A patent/PL208527B1/pl not_active IP Right Cessation
- 2003-01-22 SI SI200332197T patent/SI2045241T1/sl unknown
- 2003-01-22 DE DE60324767T patent/DE60324767D1/de not_active Expired - Lifetime
- 2003-01-22 ES ES08105552T patent/ES2391747T3/es not_active Expired - Lifetime
- 2003-01-22 EA EA200400971A patent/EA006134B1/ru not_active IP Right Cessation
- 2003-01-22 EP EP10182463.9A patent/EP2295409B1/en not_active Expired - Lifetime
- 2003-01-22 GE GE5688A patent/GEP20074078B/en unknown
- 2003-01-22 CN CN201010164113A patent/CN101851191A/zh active Pending
- 2003-01-22 UA UA20040807066A patent/UA75520C2/uk unknown
- 2003-01-22 DK DK08105552.7T patent/DK2045241T3/da active
- 2003-01-23 TW TW092101476A patent/TWI259080B/zh not_active IP Right Cessation
- 2003-01-24 DO DO2003000566A patent/DOP2003000566A/es unknown
- 2003-01-25 EG EG2003010067A patent/EG24978A/xx active
2004
- 2004-06-21 IS IS7329A patent/IS2633B/is unknown
- 2004-06-24 ZA ZA200404999A patent/ZA200404999B/en unknown
- 2004-07-01 IL IL162825A patent/IL162825A/en active IP Right Grant
- 2004-07-19 HR HR20040665 patent/HRP20040665B1/xx not_active IP Right Cessation
- 2004-07-22 EC EC2004005203A patent/ECSP045203A/es unknown
- 2004-08-24 NO NO20043536A patent/NO327322B1/no not_active IP Right Cessation
2005
- 2005-11-04 US US11/266,919 patent/US20060069148A1/en not_active Abandoned
2007
- 2007-02-26 JP JP2007045469A patent/JP2007186521A/ja active Pending
- 2007-03-02 NO NO20071193A patent/NO20071193L/no not_active Application Discontinuation
- 2007-07-23 US US11/880,557 patent/US7618994B2/en not_active Expired - Lifetime
2008
- 2008-01-17 IL IL188844A patent/IL188844A0/en unknown
2009
- 2009-02-09 CY CY20091100147T patent/CY1108841T1/el unknown
- 2009-02-20 NL NL300377C patent/NL300377I2/nl unknown
- 2009-02-27 LU LU91534C patent/LU91534I2/fr unknown
- 2009-03-12 FR FR09C0010C patent/FR09C0010I2/fr active Active
- 2009-03-31 CY CY200900004C patent/CY2009004I2/el unknown
- 2009-06-19 NO NO2009013C patent/NO2009013I2/no unknown
- 2009-09-30 US US12/570,859 patent/US20100081696A1/en not_active Abandoned
2010
- 2010-03-01 IS IS8887A patent/IS8887A/is unknown
2012
- 2012-01-19 US US13/353,974 patent/US20120115921A1/en not_active Abandoned
- 2012-09-17 CY CY20121100844T patent/CY1113330T1/el unknown

Also Published As

Publication number	Publication date
BR0307050A (pt)	2004-10-26
RS62404A (en)	2006-12-15
KR100859230B1 (ko)	2008-09-18
NO327322B1 (no)	2009-06-08
ECSP045203A (es)	2004-09-28
FR09C0010I2 (no)	2009-12-18
DOP2003000566A (es)	2003-09-15
DK1470107T3 (da)	2009-03-09
ES2316717T3 (es)	2009-04-16
AU2003202343B2 (en)	2007-07-12
CN101851191A (zh)	2010-10-06
PE20030982A1 (es)	2003-11-19
PL370427A1 (en)	2005-05-30
JP2005518413A (ja)	2005-06-23
AR038136A1 (es)	2004-12-29
IL162825A (en)	2010-12-30
ES2391747T3 (es)	2012-11-29
NL300377I1 (nl)	2009-05-06
SI2045241T1 (sl)	2012-11-30
RS51672B (en)	2011-10-31
JO2481B1 (en)	2009-01-20
EA006134B1 (ru)	2005-10-27
MXPA04007167A (es)	2004-10-29
TWI259080B (en)	2006-08-01
US20030158246A1 (en)	2003-08-21
DE122009000022I1 (de)	2009-08-06
UA75520C2 (en)	2006-04-17
EG24978A (en)	2011-04-03
JP4008885B2 (ja)	2007-11-14
US20080033028A1 (en)	2008-02-07
DE60324767D1 (de)	2009-01-02
EP2045241B1 (en)	2012-07-04
IS7329A (is)	2004-06-21
MY137040A (en)	2008-12-31
HRP20040665B1 (en)	2012-11-30
EA200400971A1 (ru)	2004-12-30
US20060069148A1 (en)	2006-03-30
IL188844A0 (en)	2009-02-11
CN1902176A (zh)	2007-01-24
NO20071193L (no)	2004-08-24
WO2003062200A2 (en)	2003-07-31
US20050124680A1 (en)	2005-06-09
EP1470107B1 (en)	2008-11-19
DK2045241T3 (da)	2012-10-15
PT1470107E (pt)	2009-01-30
CN101092388A (zh)	2007-12-26
EP2295409B1 (en)	2014-07-02
IS8887A (is)	2010-03-01
WO2003062200A3 (en)	2003-12-04
ATE414690T1 (de)	2008-12-15
NO2009013I1 (no)	2009-06-29
AU2003202343C1 (en)	2003-09-02
CY1113330T1 (el)	2016-06-22
NL300377I2 (nl)	2009-08-03
EP1470107A2 (en)	2004-10-27
TW200302090A (en)	2003-08-01
US7317036B2 (en)	2008-01-08
US7618994B2 (en)	2009-11-17
GEP20074078B (en)	2007-03-26
CY2009004I1 (el)	2009-11-04
FR09C0010I1 (no)	2009-04-17
US20100081696A1 (en)	2010-04-01
RS20100338A (en)	2011-06-30
CA2471952A1 (en)	2003-07-31
KR20070056166A (ko)	2007-05-31
NO20043536L (no)	2004-08-24
SI1470107T1 (sl)	2009-04-30
CA2471952C (en)	2008-04-01
PT2045241E (pt)	2012-09-26
KR20040075109A (ko)	2004-08-26
ZA200404999B (en)	2006-05-31
CY1108841T1 (el)	2011-04-06
CY2009004I2 (el)	2009-11-04
EP2295409A1 (en)	2011-03-16
HRP20040665A2 (en)	2005-04-30
NZ533786A (en)	2006-11-30
PL208527B1 (pl)	2011-05-31
IL162825A0 (en)	2005-11-20
JP2007186521A (ja)	2007-07-26
IS2633B (is)	2010-06-15
LU91534I2 (fr)	2009-04-27
US20120115921A1 (en)	2012-05-10
EP2045241A1 (en)	2009-04-08

Publication	Publication Date	Title
NO2009013I2 (no)	2012-08-27	Laropiprant eller et farmasøytisk akseptabelt saltderav
NO2015016I2 (no)	2015-07-09	Vorapaxar eller et farmasøytisk akseptabelt salt eller solvat derav
NO2014021I1 (no)	2014-08-20	Bedaquiline eller et farmasøytisk akseptabelt syre- eller baseaddisjonssalt derav
NO2022032I1 (no)	2022-07-22	Elvitegravir or a pharmaceutically acceptable salt thereof - Forlenget SPC
NL301177I1 (nl)	2022-06-08	tecovirimat of een farmaceutisch aanvaardbaar zout daarvan
NO2020007I1 (no)	2020-03-19	Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt
NO2015026I2 (no)	2015-12-28	panobinostat eller et farmasøytisk akseptabelt salt derav
DK2266650T3 (da)	2014-12-15	Lægemiddeldispenser
NO2014011I1 (no)	2014-05-13	Vortioksetin eller et farmasøytisk akseptabelt syreaddisjonssalt dera
IS7946A (is)	2005-07-19	Lyf
DE60334706D1 (de)	2010-12-09	Ür
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
DK1556385T3 (da)	2010-06-14	Heterocyclocarboxamid-derivater
DE60330372D1 (de)	2010-01-14	Indol-3-schwefelderivate
ATE380544T1 (de)	2007-12-15	Umhüllte feste darreichungsform
IS7720A (is)	2005-03-01	Píperidín-N-oxíð-afleiður
DK2248807T3 (da)	2013-08-26	N-Phenyl-2-pyrimidinaminderivater
IS2421B (is)	2008-10-15	Nýir etónógestrel esterar
IS7831A (is)	2005-04-28	Bóluefni
ATE335729T1 (de)	2006-09-15	3h-chinazoline -4-on derivaten
DE60328408D1 (de)	2009-08-27	Impfstoff
DE50304722D1 (de)	2006-10-05	Fungizide Wirkstoffkombinationen
DE50301814D1 (de)	2006-01-05	Nebelwurfkörper
DE50306277D1 (de)	2007-02-22	4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
NO20051561D0 (no)	2005-03-23	Vaksine

Legal Events

Date	Code	Title	Description
2013-09-09	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)